GP120 INDEPENDENT INFECTION OF CD4(-) CELLS BY HIV-1
GP120 HIV-1 对 CD4(-) 细胞的独立感染
基本信息
- 批准号:6495224
- 负责人:
- 金额:$ 25.39万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2002
- 资助国家:美国
- 起止时间:2002-05-01 至 2005-04-30
- 项目状态:已结题
- 来源:
- 关键词:AIDS therapy HIV envelope protein gp120 HIV infections T lymphocyte cell line centrifugation confocal scanning microscopy enzyme linked immunosorbent assay flow cytometry fluorescence microscopy gel electrophoresis helper T lymphocyte human immunodeficiency virus 1 latent virus infection molecular cloning polymerase chain reaction subtraction hybridization virus infection mechanism virus integration virus protein virus replication
项目摘要
We have developed a new approach to sensitively and quantitatively identify HIV-1-infected cells, and found that HIV-1 significantly infects some types of CD4(-) cells independently of gp120. Further studies have indicated that not only can CD4(-) cells be infected by HIV-1 through this mechanism, but also CD4(+) T-lymphocytes. These results propose two very important possibilities: 1) HIV-1 can exploit some types of CD4(-) cells to serve as viral reservoirs in patients; and 2) HIV-1 can reduce expression of Env in infected cells as a strategy to evade the host immune response and therefore reside in these cells as long-term low-level persistent infection in a latent state. In this application, we will quantitatively characterize gp120- independent HIV-1 infection, and elucidate the molecular mechanism by which this occurs. In Specific Aim 1, CD4(-) cell lines derived from various human tissues will be infected with three strains of HIV-1 Env(-) virus. The susceptibility of CD4(-) cells to HIV-1 infection, the rates of viral replication in infected cells, the life-span of the infected cells, and the expression of viral genes in these cell lines will be studied. The results from Aim 1 studies will be informative to assess the seriousness of overall HIV-1 infection of CD4(-) cells in patients. In Specific Aim 2, we will study the mechanism of gp120-independent infection. We will characterize the infection course of HIV-1 gp120- independent infection, including viral entry, reverse transcription, nuclear transportation, viral DNA integration, and the generation of viral RNA genomes using an HIV-susceptible CD4(-) cell line, LNCaP, infected by HIV-1 Env(-) virus. We will also identify genes that are involved in gp120-independent HIV-1 infection using subtractive hybridization. The results from these studies will be very informative for assessing the seriousness of CD4(-) cell hosted HIV-1 reservoirs in patients and for developing an approach to interrupt the infection of CD4(-) cells by HIV-1.
我们已经开发了一种新的方法来敏感和定量鉴定HIV-1感染的细胞,并发现HIV-1显着感染某些类型的CD4( - )细胞,独立于GP120。进一步的研究表明,CD4( - )细胞不仅可以通过这种机制感染HIV-1,还可以通过CD4(+)T淋巴细胞感染。这些结果提出了两种非常重要的可能性:1)HIV-1可以利用某些类型的CD4( - )细胞作为患者的病毒储层; 2)HIV-1可以减少感染细胞中ENV的表达,作为逃避宿主免疫反应的策略,因此将其作为潜在状态下的长期低水平持续感染驻留在这些细胞中。在此应用中,我们将定量地表征GP120-独立的HIV-1感染,并阐明发生这种情况的分子机制。在特定的目标1中,衍生自各种人体组织的CD4( - )细胞系将感染三种HIV-1 Env( - )病毒。 CD4( - )细胞对HIV-1感染的敏感性,感染细胞中病毒复制的速率,感染细胞的寿命以及这些细胞系中病毒基因的表达。 AIM 1研究的结果将有用,以评估患者CD4( - )细胞总体HIV-1感染的严重性。在特定目标2中,我们将研究与GP120独立感染的机制。我们将表征HIV-1 GP120-独立感染的感染过程,包括病毒式进入,逆转录,核转运,病毒DNA整合以及使用HIV敏感的CD4( - )细胞系,LNCAP,HIV-1 Enk感染的病毒RNA基因组的产生。我们还将使用减法杂交确定与GP120无关HIV-1感染有关的基因。这些研究的结果将非常有用,以评估患者中CD4( - )托管HIV-1储层的严重性以及开发一种通过HIV-1中断CD4( - )细胞感染的方法。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Shen Pang其他文献
Shen Pang的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Shen Pang', 18)}}的其他基金
A novel anti-scar peptide for cutaneous wound repair
一种用于皮肤伤口修复的新型抗疤痕肽
- 批准号:
8455289 - 财政年份:2013
- 资助金额:
$ 25.39万 - 项目类别:
A novel anti-scar peptide for cutaneous wound repair
一种用于皮肤伤口修复的新型抗疤痕肽
- 批准号:
8729393 - 财政年份:2013
- 资助金额:
$ 25.39万 - 项目类别:
GP120 INDEPENDENT INFECTION OF CD4(-) CELLS BY HIV-1
GP120 HIV-1 对 CD4(-) 细胞的独立感染
- 批准号:
6627771 - 财政年份:2002
- 资助金额:
$ 25.39万 - 项目类别:
GP120 INDEPENDENT INFECTION OF CD4(-) CELLS BY HIV-1
GP120 HIV-1 对 CD4(-) 细胞的独立感染
- 批准号:
6722820 - 财政年份:2002
- 资助金额:
$ 25.39万 - 项目类别:
TARGET SPECIFIC GENE THERAPY OF PROSTATE CANCER
前列腺癌的靶向特异性基因治疗
- 批准号:
2109239 - 财政年份:1995
- 资助金额:
$ 25.39万 - 项目类别:
TARGET SPECIFIC GENE THERAPY OF PROSTATE CANCER
前列腺癌的靶向特异性基因治疗
- 批准号:
2443130 - 财政年份:1995
- 资助金额:
$ 25.39万 - 项目类别:
TARGET SPECIFIC GENE THERAPY OF PROSTATE CANCER
前列腺癌的靶向特异性基因治疗
- 批准号:
2109238 - 财政年份:1995
- 资助金额:
$ 25.39万 - 项目类别:
TARGET SPECIFIC GENE THERAPY OF PROSTATE CANCER
前列腺癌的靶向特异性基因治疗
- 批准号:
2895221 - 财政年份:1995
- 资助金额:
$ 25.39万 - 项目类别:
TARGET SPECIFIC GENE THERAPY OF PROSTATE CANCER
前列腺癌的靶向特异性基因治疗
- 批准号:
2733121 - 财政年份:1995
- 资助金额:
$ 25.39万 - 项目类别:
相似海外基金
Quick and Accurate Measurements of HIV Broadly Neutralizing Antibody Susceptibility
快速准确地测量 HIV 广泛中和抗体敏感性
- 批准号:
10676422 - 财政年份:2023
- 资助金额:
$ 25.39万 - 项目类别:
Study to establish safety, tolerability and feasibility of LM11A-31 as a neuroprotective agent in aging people living with HIV and neurocognitive impairment on antiretroviral therapy
研究确定 LM11A-31 作为神经保护剂对老年艾滋病毒感染者和抗逆转录病毒治疗神经认知障碍患者的安全性、耐受性和可行性
- 批准号:
10762833 - 财政年份:2023
- 资助金额:
$ 25.39万 - 项目类别:
Phase II study to evaluate the efficacy and safety of baricitinib for reduction of HIV in the central nervous system
II 期研究评估 baricitinib 减少中枢神经系统 HIV 的有效性和安全性
- 批准号:
10681470 - 财政年份:2022
- 资助金额:
$ 25.39万 - 项目类别:
Phase II study to evaluate the efficacy and safety of baricitinib for reduction of HIV in the central nervous system
II 期研究评估 baricitinib 减少中枢神经系统 HIV 的有效性和安全性
- 批准号:
10484645 - 财政年份:2022
- 资助金额:
$ 25.39万 - 项目类别: